

PROGRAM OBJECTIVE

The goal of the *Medical Clinics of North America* is to keep practicing physicians up to date with current clinical practice by providing timely articles reviewing the state of the art in patient care.

TARGET AUDIENCE

All practicing physicians and other healthcare professionals.

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

1. Review the factors that are linked to psychiatric disorders and suicide.
2. Explain the appropriate use of strategies, assessment, and screening tools for use by health care clinicians of all specialties in diagnosing and treating psychiatric disorders and reducing the risk of suicide.
3. Discuss the importance of using a multidisciplinary, systematic approach to diagnosing and treating psychiatric disorders, as well as lowering the risk of suicide.

ACCREDITATION

The Elsevier Office of Continuing Medical Education (EOCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The EOCME designates this journal-based CME activity for a maximum of 11 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other healthcare professionals requesting continuing education credit for this enduring material will be issued a certificate of participation.

DISCLOSURE OF CONFLICTS OF INTEREST

The EOCME assesses conflict of interest with its instructors, faculty, planners, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by EOCME for fair balance, scientific objectivity, and patient care recommendations. EOCME is committed to providing its learners with CME activities that promote improvements or quality in healthcare and not a specific proprietary business or a commercial interest.

The planning committee, staff, authors and editors listed below have identified no financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interest related to the content of this CME activity:

Andrea Aguglia, MD, PhD; Andrea Amerio, MD, PhD; Mario Amore, MD; Rivka Benyaminov, BA; María Dolores Braquehais, MD, PhD; Jessica A. Burket, PhD; Alexander Bystritsky, MD, PhD; Carl I. Cohen, MD; Alessandra Costanza, MD; Nolan Dang, BS; Stephen I. Deutsch, MD, PhD; Margaret Distler, MD, PhD; Andrea Escelsior, MD, PhD; Justin Faden, DO; Jess G. Fiedorowicz, MD, PhD; Matthew Ganeles; Aliza Grossberg, MD, MPH; Jonathan Haroon, BS; Kurt Kroenke, MD; Helen Lavretsky, MD, MS; Luca Magnani, MD; Addie N. Merians, PhD; Dilys Ngu, MD; Katerina Nikolitch, MD, CM, MSc; Erika Nurmi, MD, PhD; Maria A. Oquendo, MD, PhD; Merlin Packiam; Robert H. Pietrzak, PhD, MPH; Valeria Placenti, MD; Collin Price, MD; Manumar Rahman, MD; Michael Reinhardt, MD; Timothy Rice, MD; Gayatri Saraf, MD; Gianluca Serafini, MD, PhD; Leo Sher, MD; Tobias Spiller, MD; Norman M. Spivak, BS; Andrew Swenson; Doreen Thomas-Payne, MSN, BSN, RN, PMHNP-BC; Alice Trabucco, MD; Scott A. Turnbull, DO; Sebastián Vargas-Cáceres, MD

The planning committee, staff, authors, and editors listed below have identified financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interest related to the content of this CME activity:

Leslie Citrome, MD, MPH; Consultant: AbbVie, Allergan, Acadia Pharmaceuticals Inc., Adamas Pharmaceuticals, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel Therapeutics Inc., Boehringer Ingelheim International GmbH, Cadent Therapeutics, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, Intra-Cellular Therapies, Janssen Pharmaceuticals, Karuna Therapeutics, Lundbeck, Lyndra Therapeutics, Merck, Neurocrine Biosciences, Novartis AG, Noven, Otsuka, Relmada Therapeutics, Reviva Pharmaceuticals Inc., Sage Therapeutics, Inc., Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals Inc., Teva Pharmaceuticals; Speaker: AbbVie, Allergan, Acadia, Alkermes, Angelini, Eisai, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Sage Therapeutics, Sunovion Pharmaceuticals, Takeda, Teva Pharmaceuticals; Stock Ownership: Bristol-Myers Squibb, Lilly, Johnson & Johnson, Merck, Pfizer Inc., Reviva Pharmaceuticals

Ilan Harpaz-Rotem, PhD: Independent Contractor: Boehringer Ingelheim International GmbH

John H. Krystal, MD: Consultant: Aptinyx, Inc., Atai Life Sciences, AstraZeneca Pharmaceuticals, Biogen, Idec, MA, Biomedisyn Corporation, Bionomics, Limited (Australia), Boehringer Ingelheim International GmbH, Cadent Therapeutics, Inc., Clexio Bioscience, Ltd., COMPASS Pathways, Limited, United Kingdom, Concert Pharmaceuticals, Inc., Epiodyne, Inc., EpiVario, Inc., Greenwich Biosciences, Inc., Heptares Therapeutics, Limited (UK), Janssen Research & Development, Jazz Pharmaceuticals, Inc., Otsuka, Perception Neuroscience Holdings, Inc., Spring Care, Inc., Sunovion Pharmaceuticals, Inc., Takeda Industries, Taisho Pharmaceutical Co., Ltd; Advisor: Biohaven Pharmaceuticals, BioXcel Therapeutics, Inc., Cadent Therapeutics, Inc., Cerevel Therapeutics, LLC, EpiVario, Inc., Eisai, Inc., Lohocla Research Corporation, Novartis Pharmaceuticals Corporation, PsychoGenics, Inc., RBNC Therapeutics, Inc., Tempero Bio, Inc., Terran Biosciences, Inc.; Stock Ownership: Biohaven Pharmaceuticals, EpiVario, Inc., RBNC Therapeutics, Inc., Sage Pharmaceuticals, Spring Care, Inc., Terran Biosciences, Inc. Tempero Bio, Inc.; Research Support: AstaZeneca Pharmaceuticals, Novartis Pharmaceutical Corporation

Marco Solmi, MD, PhD: Consultant: Angelini, Lundbeck, Otsuka

UNAPPROVED/OFF-LABEL USE DISCLOSURE

The EOCME requires CME faculty to disclose to the participants;

1. When products or procedures being discussed are off-label, unlabelled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinions. Faculty may discuss information about pharmaceutical agents that is outside of FDA-approved labelling. This information is intended solely for CME and is not intended to promote off-label use of these medications. If you have any questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

TO ENROLL

To enroll in the *Medical Clinics of North America* Continuing Medical Education program, call customer service at 1-800-654-2452 or sign up online at <http://www.theclinics.com/home/cme>. The CME program is available to subscribers for an additional annual fee of USD 324.00.

METHOD OF PARTICIPATION

In order to claim credit, participants must complete the following;

1. Complete enrolment as indicated above.
2. Read the activity.
3. Complete the CME Test and Evaluation. Participants must achieve a score of 70% on the test. All CME Tests and Evaluations must be completed online.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.